Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

FDA approval

MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

June 2, 2026

NASDAQ: $MNKD

Source: Read More

Announcements, FDA Acceptance

$MNKD, Afrezza, FDA Approval, Mealtime Insulin

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Get FREE Biotech Stock Catalyst Reports

Email

Notify me about related content and special offers.

Yes No

If you opt in above, we use this information to send related content, discounts, and other special offers.